Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cell-Easy Manufacturing Process for ATMP Approved for Clinical Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cell-Easy Manufacturing Process for ATMP Approved for Clinical Trial

Cell-Easy designed a process for the large-scale manufacturing of allogeneic treatment in compliance with the GMP standards.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cell-Easy, a French CDMO focused on advanced cell therapies, and the Toulouse University Hospital, obtained IMPD (Investigational Medicinal Product Dossier) approval from the European Medicines Agency for a first-in-human clinical trial. The trial will use an allogeneic treatment developed from an autologous process for patients with ischemic digital ulcers in systemic sclerosis. Cell-Easy developed the manufacturing process from an initially autologous one where the cell donor was the patient himself.

The allogeneic approach uses cells from a single donor to produce therapeutic doses for thousands of patients, making the process cost-efficient and more accessible for patients.

Cell-Easy has designed a process for the large-scale manufacturing of ASCs in compliance with GMP standards required by regulatory agencies. These ASCs will be used in the A-DUSE clinical trial.

“This project represents another remarkable milestone for Cell-Easy, demonstrating our ability to successfully navigate the entire life cycle of advanced therapy medicinal products (ATMP) development,” said Guillaume Costecalde, president at Cell-Easy. “Our collaborative work with physicians, supply chain partners, regulators and policymakers has enabled us to effectively address the intricacies of these therapies and establish rigorous quality standards.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics